Molgramostin

Indications
 Subcutaneous
Chemotherapy-induced neutropenia
Adult: 5-10 mcg/kg (60,000-110,000 IU/kg) daily starting 24 hr after last dose of chemotherapy and continued for 7-10 days. Max: 10 mcg/kg (110,000 IU/kg) daily.
Subcutaneous
Ganciclovir-induced neutropenia
Adult: 5 mcg/kg (60,000 IU/kg) daily. After the 5th dose, adjust dose according to neutrophil count. Max: 10 mcg/kg (110,000 IU/kg) daily.
Intravenous
Bone marrow transplantation
Adult: 10 mcg/kg (110,000 IU/kg) daily by infusion over 4-6 hr beginning on the day after the procedure and continued for 30 days depending on the neutrophil count. Max: 10 mcg/kg (110,000 IU/kg) daily.

Reconstitution: Reconstitute the lyophilised powder with 1 ml of sterile water for inj. Further dilute the reconstituted solution in 25, 50 or 100 ml infusion bags or bottles of either normal saline solution or 5% dextrose in water. Infusion admixture solution should contain a final concentration of not <7 mcg>
Overdosage Symptoms: Tachycardia, hypotension, flu-like syndrome. Treatment: Symptomatic.
Contraindications Myeloid malignancies. Lactation.
Special Precautions Patients with any pre-malignant or malignant myeloid condition, pre-existing pulmonary disease. Discontinue use in patients who develop signs of pulmonary infiltrates. Patients with fluid retention or heart failure. Regularly monitor CBC during therapy. Pregnancy.
Adverse Drug Reactions Fever and chills, nausea, dyspnoea, diarrhoea, rash, rigors, inj site reaction (SC admin), vomiting, fatigue, anorexia, bone and musculoskeletal pain, asthenia, transient hypotension, non-specific chest pain, stomatitis, headache, increased sweating, abdominal pain, pruritus, dizziness, peripheral oedema, paraesthesia and myalgia. Antibodies can develop.
Potentially Fatal: Anaphylactic reactions, pleural and pericardial effusion, cardiac arrhythmias.
Drug Interactions May increase occurrence of bleomycin-induced pulmonary toxicity.
Potentially Fatal: Increased risk of myelosuppression when given simultaneously with myelosuppressive cytotoxic antineoplastics. Do not use within 24 hr of cytotoxic chemotherapy.
See Below for More molgramostim Drug Interactions
Storage Intravenous: Store at 2-8°C. Do not freeze. Protect from light. Subcutaneous: Store at 2-8°C. Do not freeze. Protect from light.
Mechanism of Action Molgramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF) that influences the growth, differentiation and function of the granulocytes, macrophages and eosinophils. It helps in the separation of granulocyte and macrophage pathways and also enhances cell function.
CIMS Class Haematopoietic Agents
ATC Classification L03AA03 - molgramostim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
 
Related molgramostim information:
Drugs interacting with molgramostim
Find molgramostim in other countries
Search molgramostim in Google
Search molgramostim in PubMed
 
Search related pubmed documents for molgramostim by indication/synonym:
Adjunct to antineoplastic therapy
Ganciclovir-induced neutropenia
Bone marrow transplantation
Contraindications
 Myeloid malignancies. Lactation.
Warnings / Precautions
 Patients with any pre-malignant or malignant myeloid condition, pre-existing pulmonary disease. Discontinue use in patients who develop signs of pulmonary infiltrates. Patients with fluid retention or heart failure. Regularly monitor CBC during therapy. Pregnancy.
Adverse Reactions
 Fever and chills, nausea, dyspnoea, diarrhoea, rash, rigors, inj site reaction (SC admin), vomiting, fatigue, anorexia, bone and musculoskeletal pain, asthenia, transient hypotension, non-specific chest pain, stomatitis, headache, increased sweating, abdominal pain, pruritus, dizziness, peripheral oedema, paraesthesia and myalgia. Antibodies can develop.
Potentially Fatal: Anaphylactic reactions, pleural and pericardial effusion, cardiac arrhythmias.
Overdose Reactions
 Symptoms: Tachycardia, hypotension, flu-like syndrome. Treatment: Symptomatic.
Drug Interactions
 May increase occurrence of bleomycin-induced pulmonary toxicity.
Potentially Fatal: Increased risk of myelosuppression when given simultaneously with myelosuppressive cytotoxic antineoplastics. Do not use within 24 hr of cytotoxic chemotherapy.
See Below for More molgramostim Drug Interactions
Mechanism of Actions
 Molgramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF) that influences the growth, differentiation and function of the granulocytes, macrophages and eosinophils. It helps in the separation of granulocyte and macrophage pathways and also enhances cell function.
Storage Conditions
 Intravenous: Store at 2-8°C. Do not freeze. Protect from light. Subcutaneous: Store at 2-8°C. Do not freeze. Protect from light.
ATC Classification
 L03AA03 - molgramostim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
Storage
 Intravenous: Store at 2-8°C. Do not freeze. Protect from light. Subcutaneous: Store at 2-8°C. Do not freeze. Protect from light.
Available As
  • Molgramostin 150 mcg
  • Molgramostin 300 mcg
  • Molgramostin 400 mcg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Molgramostin


    Molgramostin Containing Brands

    We are Developing Our database, More results coming soon.

    Molgramostin is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Molgramostin

    We are Developing Our database, More results coming soon.